Source: Annual Congress 2012 - Effectiveness of therapeutic interventions in primary care
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Fabbri, U. M. Goehring, M. Brose, K. Rabe (Modena, Italy; Konstanz, Wöhrendamm, Germany). Effects of roflumilast in highly symptomatic COPD patients. Eur Respir J 2012; 40: Suppl. 56, 742

Member's Comments

No comment yet.

Related content which might interest you: Effect of roflumilast on hospitalizations in COPD patients Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Long-term effect of roflumilast on exacerbations in patients with severe to very severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 526s Year: 2006 Effect of roflumilast in patients with severe COPD and a history of hospitalisation Source: Eur Respir J, 50 (1) 1700158; 10.1183/13993003.00158-2017 Year: 2017 The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients Source: Eur Respir J 2014; 44: 527-529 Year: 2014 Efficacy of roflumilast in the frequent exacerbation COPD phenotype Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Effect of erdosteine in moderately severe COPD patients Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Clinical and functional effectiveness of roflumilast in severe COPD patients Source: Annual Congress 2013 –Modern approach to various clinical settings Year: 2013 Efficacy of the PDE4 inhibitor roflumilast in COPD patients with chronic bronchitis Source: Annual Congress 2009 - Treatment of COPD Year: 2009 Effect of azithromycin treatment on inflammation in COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Neutrophils and spirometry changes in COPD patients treated with roflumilast Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease Year: 2015 Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Pharmacological activities of roflumilast N-oxide, dexamethasone and formoterol in human neutrophils from healthy non-smokers and COPD patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 The effect of tiotropium in the treatment of patients with COPD Source: Annual Congress 2010 - COPD: management Year: 2010 Salmeterol 50μg bid significantly reduces moderate-severe exacerbations in patients with all severities of COPD Source: Eur Respir J 2003; 22: Suppl. 45, 68s Year: 2003 Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013 QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Effects of Hochuekkito combined with pulmonary rehabilitation in patients with COPD Source: International Congress 2017 – Latest insights into pulmonary rehabilitation in COPD Year: 2017 Effects of bosentan in patients with severe pulmonary hypertension and mild-to-moderate COPD Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001 Safety of the PDE4 inhibitor roflumilast in COPD patients with chronic bronchitis Source: Annual Congress 2009 - Treatment of COPD Year: 2009